Abstract
We acknowledge the central issue: namely, the heterogeneity of patients recruited related to the lack of clear consensus regarding the pathophysiology of HFpEF and the inability of traditional diagnostic techniques, such as resting echocardiography, to diagnose this condition.
| Original language | English |
|---|---|
| Pages (from-to) | e604 |
| Journal | Circulation |
| Volume | 133 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 19 Apr 2016 |
Fingerprint
ASJC Scopus subject areas
- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Cite this
Response to Letter Regarding Article, "the Effect of Selective Heart Rate Slowing in Heart Failure with Preserved Ejection Fraction". / Pal, Nikhil; Sivaswamy, Nadiya; Mahmod, Masliza; Yavari, Arash; Rudd, Amelia; Singh, Satnam; Dawson, Dana K.; Francis, Jane M.; Dwight, Jeremy S.; Watkins, Hugh; Neubauer, Stefan; Frenneaux, Michael; Ashrafian, Houman.
In: Circulation, Vol. 133, No. 16, 19.04.2016, p. e604.Research output: Contribution to journal › Letter
}
TY - JOUR
T1 - Response to Letter Regarding Article, "the Effect of Selective Heart Rate Slowing in Heart Failure with Preserved Ejection Fraction"
AU - Pal, Nikhil
AU - Sivaswamy, Nadiya
AU - Mahmod, Masliza
AU - Yavari, Arash
AU - Rudd, Amelia
AU - Singh, Satnam
AU - Dawson, Dana K.
AU - Francis, Jane M.
AU - Dwight, Jeremy S.
AU - Watkins, Hugh
AU - Neubauer, Stefan
AU - Frenneaux, Michael
AU - Ashrafian, Houman
PY - 2016/4/19
Y1 - 2016/4/19
N2 - We thank de Dios for their comments related to the differences in outcomes noted between our observations and previously published work exploring the role of ivabradine in patients with heart failure with preserved ejection fraction (HFpEF).1We acknowledge the central issue: namely, the heterogeneity of patients recruited related to the lack of clear consensus regarding the pathophysiology of HFpEF and the inability of traditional diagnostic techniques, such as resting echocardiography, to diagnose this condition.
AB - We thank de Dios for their comments related to the differences in outcomes noted between our observations and previously published work exploring the role of ivabradine in patients with heart failure with preserved ejection fraction (HFpEF).1We acknowledge the central issue: namely, the heterogeneity of patients recruited related to the lack of clear consensus regarding the pathophysiology of HFpEF and the inability of traditional diagnostic techniques, such as resting echocardiography, to diagnose this condition.
UR - http://www.scopus.com/inward/record.url?scp=84964506820&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.116.021488
DO - 10.1161/CIRCULATIONAHA.116.021488
M3 - Letter
AN - SCOPUS:84964506820
VL - 133
SP - e604
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 16
ER -